RPRD2

Summary

RPRD2 (regulation of nuclear pre-mRNA domain containing 2, HGNC:29039) is a protein-coding gene on chromosome 1q21.2, encoding Regulation of nuclear pre-mRNA domain-containing protein 2 (Q5VT52). It is a selective cancer dependency (DepMap: 12.3% of cell lines).

Predicted to enable RNA polymerase II complex binding activity. Predicted to be involved in mRNA 3’-end processing. Part of transcription preinitiation complex.

Source: NCBI Gene 23248 — RefSeq curated summary.

At a glance

• GWAS associations: 16
• Clinical variants (ClinVar): 171 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• Cancer dependency (DepMap): dependent in 12.3% of screened cell lines
• MANE Select transcript: NM_015203

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29039
Approved symbol	RPRD2
Name	regulation of nuclear pre-mRNA domain containing 2
Location	1q21.2
Locus type	gene with protein product
Status	Approved
Aliases	FLJ32145, HSPC099
Ensembl gene	ENSG00000163125
Ensembl biotype	protein_coding
OMIM	614695
Entrez	23248

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 6 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000369067, ENST00000369068, ENST00000401000, ENST00000492220, ENST00000879564, ENST00000879565, ENST00000912741

RefSeq mRNA: 14 — MANE Select: NM_015203 NM_001297673, NM_001297674, NM_001387114, NM_001387115, NM_001387116, NM_001387117, NM_001387118, NM_001387119, NM_001387120, NM_001387121, NM_001387122, NM_001387123, NM_001387124, NM_015203

CCDS: CCDS44216, CCDS72907

Canonical transcript exons

ENST00000369068 — 11 exons

Exon	Start	End
ENSE00001152765	150441881	150441958
ENSE00001310077	150470561	150476566
ENSE00001921038	150364147	150364919
ENSE00003484463	150464527	150464727
ENSE00003506959	150443231	150443283
ENSE00003524930	150460060	150460317
ENSE00003535813	150417596	150417725
ENSE00003556770	150446226	150446401
ENSE00003610396	150444251	150444377
ENSE00003625524	150440923	150441023
ENSE00003686784	150457288	150457570

Expression profiles

Bgee: expression breadth ubiquitous, 293 present calls, max score 96.53.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 28.1481 / max 257.3151, expressed in 1809 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
5103	12.6428	1781
5098	6.5803	1592
5099	5.5325	1534
5102	1.4455	921
5096	0.8946	369
5097	0.5527	311
5101	0.2798	143
5100	0.2201	107

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
buccal mucosa cell	CL:0002336	96.53	gold quality
superficial temporal artery	UBERON:0001614	95.03	gold quality
oocyte	CL:0000023	94.96	gold quality
olfactory bulb	UBERON:0002264	94.54	silver quality
diaphragm	UBERON:0001103	94.40	silver quality
nipple	UBERON:0002030	94.39	gold quality
endothelial cell	CL:0000115	94.25	gold quality
renal medulla	UBERON:0000362	94.13	gold quality
cardia of stomach	UBERON:0001162	93.86	gold quality
germinal epithelium of ovary	UBERON:0001304	93.20	gold quality
pylorus	UBERON:0001166	92.62	gold quality
type B pancreatic cell	CL:0000169	92.34	silver quality
inferior vagus X ganglion	UBERON:0005363	92.22	gold quality
gingival epithelium	UBERON:0001949	92.00	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	91.86	gold quality
ventral tegmental area	UBERON:0002691	91.71	gold quality
endometrium epithelium	UBERON:0004811	91.67	gold quality
dorsal root ganglion	UBERON:0000044	91.18	gold quality
mucosa of paranasal sinus	UBERON:0005030	91.12	gold quality
trigeminal ganglion	UBERON:0001675	91.10	gold quality
CA1 field of hippocampus	UBERON:0003881	90.96	gold quality
middle temporal gyrus	UBERON:0002771	90.80	gold quality
superior surface of tongue	UBERON:0007371	90.62	gold quality
medial globus pallidus	UBERON:0002477	90.61	gold quality
vastus lateralis	UBERON:0001379	90.59	gold quality
subthalamic nucleus	UBERON:0001906	90.50	gold quality
saphenous vein	UBERON:0007318	90.47	gold quality
left ventricle myocardium	UBERON:0006566	90.32	gold quality
pericardium	UBERON:0002407	90.27	gold quality
medulla oblongata	UBERON:0001896	90.13	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): YY1

miRNA regulators (miRDB)

142 targeting RPRD2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-552-5P	99.93	68.56	1583
HSA-MIR-548AE-3P	99.93	72.66	4867

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 12.3% of screened cell lines.

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	rprd2a	ENSDARG00000058089
danio_rerio	rprd2b	ENSDARG00000074676
mus_musculus	Rprd2	ENSMUSG00000028106
rattus_norvegicus	Rprd2	ENSRNOG00000054294
drosophila_melanogaster	CG15160	FBGN0032688
caenorhabditis_elegans	cids-2	WBGENE00009451

Paralogs (2): RPRD1B (ENSG00000101413), RPRD1A (ENSG00000141425)

Protein

Protein identifiers

Regulation of nuclear pre-mRNA domain-containing protein 2 — Q5VT52 (reviewed: Q5VT52)

All UniProt accessions (1): Q5VT52

UniProt curated annotations — full annotation on UniProt →

Subunit / interactions. Associates with the RNA polymerase II complex.

Isoforms (5)

UniProt ID	Names	Canonical?
Q5VT52-1	1	yes
Q5VT52-2	2
Q5VT52-3	3
Q5VT52-4	4
Q5VT52-5	5

RefSeq proteins (14): NP_001284602, NP_001284603, NP_001374043, NP_001374044, NP_001374045, NP_001374046, NP_001374047, NP_001374048, NP_001374049, NP_001374050, NP_001374051, NP_001374052, NP_001374053, NP_056018* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006569	CID_dom	Domain
IPR008942	ENTH_VHS	Homologous_superfamily
IPR047885	RPRD2_CID	Domain

Pfam: PF04818

UniProt features (90 total): modified residue 37, compositionally biased region 20, helix 9, region of interest 8, splice variant 6, sequence conflict 4, turn 2, initiator methionine 1, chain 1, domain 1, sequence variant 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
4FLB	X-RAY DIFFRACTION	1.8
9HM8	SOLUTION NMR
9IA7	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5VT52-F1	48.32	0.14

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (37): 2, 16, 356, 358, 374, 473, 476, 479, 482, 485, 517, 564, 593, 598, 614, 663, 665, 716, 723, 730 …

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-6807505	RNA polymerase II transcribes snRNA genes
R-HSA-73857	RNA Polymerase II Transcription
R-HSA-74160	Gene expression (Transcription)

MSigDB gene sets: 197 (showing top): HORIUCHI_WTAP_TARGETS_DN, MAZ_Q6, GAUSSMANN_MLL_AF4_FUSION_TARGETS_C_UP, AREB6_01, TGACCTY_ERR1_Q2, GGGTGGRR_PAX4_03, PATIL_LIVER_CANCER, MORF_RAF1, YY1_02, MORF_FANCG, GOBP_MRNA_3_END_PROCESSING, GFI1_01, WHN_B, ZHANG_BREAST_CANCER_PROGENITORS_UP, MORF_IKBKG

GO Biological Process (1): mRNA 3’-end processing (GO:0031124)

GO Molecular Function (2): RNA polymerase II complex binding (GO:0000993), RNA polymerase II C-terminal domain binding (GO:0099122)

GO Cellular Component (2): nucleoplasm (GO:0005654), transcription preinitiation complex (GO:0097550)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
RNA Polymerase II Transcription	1
Gene expression (Transcription)	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
mRNA processing	1
RNA 3’-end processing	1
RNA polymerase core enzyme binding	1
RNA polymerase II complex binding	1
nuclear lumen	1
cellular anatomical structure	1
protein-DNA complex	1

Protein interactions and networks

STRING

1330 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RPRD2	RPAP2	Q8IXW5	777
RPRD2	RECQL5	O94762	570
RPRD2	SCAF8	Q9UPN6	566
RPRD2	PCF11	O94913	556
RPRD2	PRRC2C	Q9Y520	513
RPRD2	GPN1	Q9HCN4	511
RPRD2	BCL7A	Q4VC05	492
RPRD2	SCAF4	O95104	490
RPRD2	ZNF462	Q96JM2	449
RPRD2	RPAP3	Q9H6T3	448
RPRD2	FAM171B	Q6P995	443
RPRD2	CD164L2	Q6UWJ8	429
RPRD2	TFAP4	Q01664	425
RPRD2	MCM7	P33993	418
RPRD2	RAB39A	Q14964	401

IntAct

87 interactions, top by confidence:

A	B	Type	Score
POLR2J	POLR1C	psi-mi:“MI:0914”(association)	0.830
HSPA8	GAK	psi-mi:“MI:0914”(association)	0.760
POLR2D	MED19	psi-mi:“MI:0914”(association)	0.730
POLR2E	MED19	psi-mi:“MI:0914”(association)	0.730
RPRD1B	POLR2D	psi-mi:“MI:0914”(association)	0.730
RPRD1B	RECQL5	psi-mi:“MI:0914”(association)	0.730
POLR2G	RECQL5	psi-mi:“MI:0914”(association)	0.730
POLR2J	POLR2D	psi-mi:“MI:0914”(association)	0.730
POLR2L	RCCD1	psi-mi:“MI:0914”(association)	0.640
HIF1AN	GMDS	psi-mi:“MI:0914”(association)	0.640
SUPT5H	POLR2D	psi-mi:“MI:0914”(association)	0.530
BAG2	HGS	psi-mi:“MI:0914”(association)	0.530
POLR2M	BIN1	psi-mi:“MI:0914”(association)	0.530
POLR2J	MED14	psi-mi:“MI:0914”(association)	0.530
CPSF6	DDX39A	psi-mi:“MI:0914”(association)	0.480
RPRD2	H1-5	psi-mi:“MI:0915”(physical association)	0.400
RPRD2	WWOX	psi-mi:“MI:0915”(physical association)	0.400
RPRD2	CTDSP1	psi-mi:“MI:0915”(physical association)	0.370
RPRD2	PPP1CA	psi-mi:“MI:0915”(physical association)	0.370
Rprd1b	POLR2B	psi-mi:“MI:0914”(association)	0.350
JUN		psi-mi:“MI:0914”(association)	0.350
Xpo1	IFT56	psi-mi:“MI:0914”(association)	0.350
HIF1AN	CNOT1	psi-mi:“MI:0914”(association)	0.350
POLR2M	MED19	psi-mi:“MI:0914”(association)	0.350
RPAP2	APOC3	psi-mi:“MI:0914”(association)	0.350
RPRD1A	RECQL5	psi-mi:“MI:0914”(association)	0.350
RPS6KL1	GOLIM4	psi-mi:“MI:0914”(association)	0.350
LIN28A	AGPS	psi-mi:“MI:0914”(association)	0.350

BioGRID (197): RPRD2 (Affinity Capture-MS), RPRD2 (Affinity Capture-MS), RPRD2 (Affinity Capture-MS), RPRD2 (Proximity Label-MS), RPRD2 (Affinity Capture-MS), RPRD2 (Affinity Capture-MS), RPRD2 (Affinity Capture-MS), RPRD2 (Affinity Capture-MS), RPRD2 (Affinity Capture-MS), RPRD2 (Affinity Capture-MS), RPRD2 (Affinity Capture-MS), RPRD2 (Affinity Capture-MS), RPRD2 (Affinity Capture-MS), RPRD2 (Affinity Capture-MS), RPRD2 (Synthetic Lethality)

ESM2 similar proteins: A0JNI5, A2AJT4, D3ZTQ1, O75151, O75376, P35269, P49140, P70501, P98175, Q05519, Q12872, Q2NLB0, Q3THK3, Q3UQU0, Q3USH5, Q3ZC82, Q4KKX4, Q53F19, Q5BL56, Q5EA53, Q5HZB6, Q5SFM8, Q5T8P6, Q5U3K5, Q5VT52, Q5ZM19, Q60974, Q62415, Q6AY96, Q6DFQ2, Q6NXI6, Q6NZN0, Q6PJT7, Q6WKW9, Q6ZQ03, Q7Z7F0, Q80TJ7, Q80WC1, Q8BZR9, Q8CFC7

Diamond homologs: Q5VT52, Q6NXI6, Q9CSU0, Q9NQG5, Q5ZM30, Q0P5J9, Q5R8Y3, Q8VDS4, Q96P16

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 109 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
FGFR2 mutant receptor activation	6	55.0×	2e-08
Signaling by FGFR2 IIIa TM	6	43.5×	5e-08
Activation of HOX genes during differentiation	8	42.3×	4e-10
Abortive elongation of HIV-1 transcript in the absence of Tat	7	41.9×	5e-09
FGFR2 alternative splicing	7	35.7×	2e-08
Pausing and recovery of Tat-mediated HIV elongation	8	35.5×	1e-09
Tat-mediated HIV elongation arrest and recovery	8	35.5×	1e-09
RNA Pol II CTD phosphorylation and interaction with CE during HIV infection	7	34.4×	2e-08

GO biological processes:

GO term	Partners	Fold	FDR
spliceosomal snRNP assembly	5	29.6×	1e-04
positive regulation of transcription elongation by RNA polymerase II	5	15.3×	2e-03
mRNA transport	5	13.4×	3e-03
mRNA splicing, via spliceosome	14	13.1×	2e-09
negative regulation of translation	6	12.0×	1e-03
RNA splicing	11	9.9×	5e-06
mRNA processing	10	8.0×	1e-04
transcription by RNA polymerase II	8	5.8×	5e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

171 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	150
Likely benign	8
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1946 predictions. Top by Δscore:

Variant	Effect	Δscore
1:150364915:GAGAT:G	donor_gain	1.0000
1:150364917:GAT:G	donor_gain	1.0000
1:150364918:ATG:A	donor_loss	1.0000
1:150364919:TGTG:T	donor_loss	1.0000
1:150364920:G:C	donor_loss	1.0000
1:150364920:G:GG	donor_gain	1.0000
1:150364921:T:A	donor_loss	1.0000
1:150417584:T:TA	acceptor_gain	1.0000
1:150417588:A:AG	acceptor_gain	1.0000
1:150417589:T:G	acceptor_gain	1.0000
1:150417594:A:AG	acceptor_gain	1.0000
1:150417595:G:GG	acceptor_gain	1.0000
1:150417595:GCT:G	acceptor_gain	1.0000
1:150417595:GCTGC:G	acceptor_gain	1.0000
1:150417721:GTGAA:G	donor_gain	1.0000
1:150417722:TGAA:T	donor_gain	1.0000
1:150417723:GAA:G	donor_gain	1.0000
1:150417723:GAAG:G	donor_gain	1.0000
1:150417724:AA:A	donor_gain	1.0000
1:150417725:AGTA:A	donor_loss	1.0000
1:150417726:GTAA:G	donor_gain	1.0000
1:150417727:T:G	donor_loss	1.0000
1:150440914:T:TA	acceptor_gain	1.0000
1:150440919:TCAG:T	acceptor_loss	1.0000
1:150440920:CAGG:C	acceptor_loss	1.0000
1:150440921:A:AG	acceptor_gain	1.0000
1:150440921:AG:A	acceptor_gain	1.0000
1:150440921:AGG:A	acceptor_gain	1.0000
1:150440922:G:GC	acceptor_gain	1.0000
1:150440922:GG:G	acceptor_gain	1.0000

AlphaMissense

9481 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:150364832:T:C	S40P	1.000
1:150364836:T:A	I41N	1.000
1:150364848:C:G	S45W	1.000
1:150364853:T:A	W47R	1.000
1:150364853:T:C	W47R	1.000
1:150364856:T:C	C48R	1.000
1:150364858:T:G	C48W	1.000
1:150364898:T:A	W62R	1.000
1:150364898:T:C	W62R	1.000
1:150417620:T:C	L77P	1.000
1:150417625:T:G	Y79D	1.000
1:150417629:T:A	L80H	1.000
1:150417629:T:C	L80P	1.000
1:150417632:C:A	A81D	1.000
1:150417636:T:A	N82K	1.000
1:150417636:T:G	N82K	1.000
1:150417637:G:C	D83H	1.000
1:150417637:G:T	D83Y	1.000
1:150417638:A:C	D83A	1.000
1:150417638:A:G	D83G	1.000
1:150417638:A:T	D83V	1.000
1:150417641:T:A	V84D	1.000
1:150417644:T:A	I85K	1.000
1:150417644:T:G	I85R	1.000
1:150417647:A:C	Q86P	1.000
1:150417648:G:C	Q86H	1.000
1:150417648:G:T	Q86H	1.000
1:150417651:C:A	N87K	1.000
1:150417651:C:G	N87K	1.000
1:150417652:T:C	C88R	1.000

dbSNP variants (sampled 300 via entrez): RS1000046427 (1:150453652 A>T), RS1000064607 (1:150417925 T>C), RS1000128515 (1:150411175 A>G), RS1000220430 (1:150389819 A>G), RS1000235766 (1:150371858 G>C,T), RS1000246963 (1:150424639 T>C), RS1000298767 (1:150447077 C>G,T), RS1000421014 (1:150440344 A>C,G), RS1000426630 (1:150461070 A>G), RS1000461373 (1:150377627 A>G,T), RS1000541989 (1:150394117 C>G), RS1000626312 (1:150411338 G>A,T), RS1000665205 (1:150429079 A>G), RS1000671095 (1:150388401 C>A,T), RS1000797660 (1:150382415 G>T)

Disease associations

OMIM: gene MIM:614695 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

16 associations (top):

Study	Trait	p-value
GCST004946_24	Schizophrenia	5.000000e-09
GCST007255_1	Broad depression or bipolar disorder	6.000000e-08
GCST008524_9	Bitter non-alcoholic beverage consumption	1.000000e-07
GCST010002_366	Refractive error	3.000000e-15
GCST010696_11	Cortical thickness (min-P)	2.000000e-23
GCST010697_17	Cortical surface area (min-P)	9.000000e-09
GCST010698_23	Subcortical volume (min-P)	2.000000e-08
GCST010699_48	Brain morphology (min-P)	3.000000e-08
GCST010700_28	Cortical thickness (MOSTest)	8.000000e-38
GCST010701_113	Cortical surface area (MOSTest)	9.000000e-12
GCST010702_126	Subcortical volume (MOSTest)	4.000000e-09
GCST010703_244	Brain morphology (MOSTest)	9.000000e-12
GCST011124_1	Caffeine consumption from tea	6.000000e-10
GCST012497_1	Lung function (FEV1)	5.000000e-06
GCST90000582_6	Spontaneous coronary artery dissection	5.000000e-12
GCST90002398_492	Neutrophil count	3.000000e-13

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0010093	bitter non-alcoholic beverage consumption measurement
EFO:0004346	neuroimaging measurement
EFO:0004840	cortical thickness
EFO:0010091	tea consumption measurement
EFO:0004314	forced expiratory volume
EFO:0004833	neutrophil count

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5725129 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,538 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1232461	MOLIBRESIB	2	1,538

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

1 potent at pChembl≥5 of 1 total, top 1 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.29	IC50	5110	nM	MOLIBRESIB

PubChem BioAssay actives

1 with measured affinity, of 6 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide	2178738: Inhibition of RPRD2 (unknown origin) incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	ic50	5.1100	uM

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases expression, affects expression, affects cotreatment	5
trichostatin A	decreases expression, affects expression, affects cotreatment	3
sodium arsenite	affects cotreatment, increases expression, decreases expression, increases abundance	2
Benzo(a)pyrene	decreases methylation, decreases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Cadmium Chloride	increases abundance, decreases expression	2
aristolochic acid I	decreases expression	1
FR900359	affects phosphorylation	1
dicrotophos	increases expression	1
triphenyl phosphate	affects expression	1
nobiletin	decreases expression, decreases reaction	1
sodium arsenate	decreases expression, decreases reaction	1
butyraldehyde	decreases expression	1
manganese chloride	decreases expression, increases abundance, affects cotreatment	1
ferrous chloride	decreases expression	1
aflatoxin B2	decreases methylation	1
coumarin	affects phosphorylation	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
ICG 001	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
3-(2-hydroxy-4-(2-methylnonan-2-yl)phenyl)cyclohexan-1-ol	decreases expression	1
Acetaminophen	decreases expression	1
Air Pollutants	increases abundance, affects expression	1
Arsenic	affects cotreatment, decreases expression, increases abundance	1
Cadmium	decreases expression, increases abundance	1
Caffeine	affects phosphorylation	1
Cisplatin	decreases expression	1
Doxorubicin	decreases expression	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1
Ivermectin	decreases expression	1

ChEMBL screening assays

6 unique, capped per target: 6 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5697468	Binding	Inhibition of RPRD2 (unknown origin) assessed as fold change at 10 uM incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. — Nature

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.